𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomized, double-blind trial of transcranial electrostimulation in early Parkinson's disease

✍ Scribed by Holly A. Shill; Sanja Obradov; Yakov Katsnelson; Ray Pizinger

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
90 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We studied the effects of noninvasive transcranial electrical stimulation on the motor and psychological symptoms of early Parkinson's disease. Twenty‐three subjects were treated with 10 days of placebo versus active treatment and then followed for 14 weeks. Baseline off medication Unified Parkinson's Disease Rating Scale parts I–III was 29.4 ± 10.0. The primary end point, Unified Parkinson's Disease Rating Scale in week 2 following treatment, reduced by 5.3 ± 9.7 for those in active treatment and 7.7 ± 4.8 for those receiving placebo (not significant). Similarly, no significant differences were seen in the Hamilton Anxiety Scale, Geriatric Depression Scale, and Epworth Sleepiness Scale over the duration of the study. The treatment was well tolerated without device‐related adverse events. Despite the negative study, nonpharmacological approaches should continue to be pursued in Parkinson's disease, as they are generally well received by patients. © 2011 Movement Disorder Society

📜 SIMILAR VOLUMES

Pardoprunox in early Parkinson's disease
Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials
✍ Cristina Sampaio; Juliana Bronzova; Robert A. Hauser; Anthony E. Lang; Olivier R 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 1 views

## Abstract This report presents the results of 2 randomized trials—Rembrandt and Vermeer—on the efficacy and safety of pardoprunox in patients with early Parkinson's disease. Patients with Parkinson's disease with a Unified Parkinson's Disease Rating Scale–Motor score ≥ 10 and modified Hoehn and Y

Double-blind, randomized, controlled tri
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
✍ Matthew B. Stern; Kenneth L. Marek; Joseph Friedman; Robert A. Hauser; Peter A. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 2 views

## Abstract Rasagiline (__N__‐propargyl‐1(__R__)‐aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase‐B inhibitor. This study was designed to evaluate the safety, tolerability, and preliminary efficacy of rasagiline monotherapy in early Parkinson's disease (PD) patients n

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

Double-blind trial of levodopa/carbidopa
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease
✍ Robert A. Hauser; Michel Panisset; Giovanni Abbruzzese; Linda Mancione; Nalina D 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

## Abstract We performed a 39‐week, randomized, double‐blind, multicenter study to compare the efficacy, safety, and tolerability of levodopa/carbidopa/entacapone (LCE, Stalevo) with levodopa/carbidopa (LC, Sinemet IR) in patients with early Parkinson's disease (PD). Four hundred twenty‐three patie

Randomized, double-blind, pilot evaluati
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
✍ Robert A. Hauser; Kelly E. Lyons; Terry McClain; Summer Carter; David Perlmutter 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

## Abstract The objective of this study was to evaluate the safety, tolerability, and preliminary efficacy of intravenous glutathione in Parkinson's disease (PD) patients. This was a randomized, placebo‐controlled, double‐blind, pilot trial in subjects with PD whose motor symptoms were not adequate

Randomized, double-blind, multicenter ev
Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease
✍ Robert A. Hauser; Anthony H.V. Schapira; Olivier Rascol; Paolo Barone; Yoshikuni 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 1 views

## Abstract The objective of this study was to evaluate the efficacy and safety of pramipexole extended release (ER) administered once daily in early Parkinson's disease (PD). Pramipexole immediate release (IR) administered three times daily (TID) is an efficacious and generally well‐tolerated trea